SjDCCR2Post

1. What Sjogren’s patients should receive a CT chest to evaluate for interstitial lung disease?
2. What are common lung manifestations of Sjögren’s disease (SjD)?

Learning Objectives

Rows	Poor	Fair	Good	Very Good	Excellent
Discuss the immune pathophysiology of Sjögren’s disease with special attention to signaling pathways involving B and T cells, the role of autoantibodies as biomarkers of disease, and the related mechanism of action of a novel dual cytokine BLyS (BAFF) and APRIL inhibitor
Analyze the most up to date clinical trial data for emerging therapies, including that of a novel dual cytokine BLyS (BAFF) and APRIL inhibitor, in the management of patients with Sjögren’s disease
Review treatment strategies for the potential role of a novel dual cytokine BLyS (BAFF) and APRIL inhibitor to address pathophysiology and improve the management of currently unmet patient needs in Sjögren’s disease

Do you feel this activity was fair balanced and free of commercial bias?
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
This educational activity will result in a change in my practice behavior.
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
What factors beyond clinical care that effect the health of your patients does your team experience?
Date
Course Title
Credits
Attestation to time spent on activity:

AcademicCME designates this live activity for a maximum of 0.50 AMA PRA Category 1 Credits™, 0.50 CNE Contact Hours (Provider #P0491) or 0.50 CPE Contact Hours (0.05 CEUs) UAN #JA4008190-0000-26-009-L01-P.
Please select your credit type from the below:
AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.
Should be Empty: